Palo Alto‑based Evommune filed for an initial public offering to fund late‑stage development of two oral or biologic candidates for chronic spontaneous urticaria and atopic dermatitis. The company’s lead oral candidate targets the mast‑cell receptor MRGPRX2 (EVO756); a second program (EVO301) neutralizes IL‑18. Evommune reported encouraging Phase‑2 data and expects Phase‑2 readouts in the coming year. Evommune’s S‑1 notes $87 million cash on hand and prior $267 million in private financing. The planned IPO would support pivotal studies and broader development across inflammatory indications; investors will watch upcoming Phase‑2 readouts for clinical differentiation versus existing biologics.